Global Leading Market Research Publisher QYResearch announces the release of its latest report “Mobile CIP and SIP Devices – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Mobile CIP and SIP Devices market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Mobile CIP and SIP Devices was estimated to be worth US816millionin2025andisprojectedtoreachUS816millionin2025andisprojectedtoreachUS 1,371 million, growing at a CAGR of 7.8% from 2026 to 2032. In 2024, global sales of mobile CIP and SIP devices reached 21,000 units, with an average selling price of approximately US$ 38,800 per unit. Mobile CIP and SIP devices are a type of mobile cleaning and sterilization system used in the pharmaceutical, food and beverage, and biotechnology industries. They enable equipment cleaning-in-place (CIP) — automated circulation of cleaning solutions (caustic, acid, rinse water) through process piping, vessels, and filling lines without disassembly — and sterilization-in-place (SIP) — using saturated steam (121-140°C) or superheated water to achieve sterility assurance level (SAL 10⁻⁶), eliminating microbial contaminants including bacterial spores. These mobile systems significantly improve production process hygiene and regulatory compliance (cGMP, FDA 21 CFR Part 211, EU GMP Annex 1, FSMA). They also offer flexible deployment (can be wheeled between production suites or rented for campaign manufacturing and multi-product facilities), high automation (PLC-controlled, recipe-driven cycles with electronic batch records and data logging for audit trail 21 CFR Part 11 compliance), and labor savings (reduces manual cleaning hours by 70-85% compared to disassembly/manual wash down). Upstream raw materials include stainless steel (304/316L or electropolished 316L for bio/pharma bioburden reduction), pump and valve components (sanitary centrifugal pumps, diaphragm valves, seat valves, air-operated valves, all wetted surfaces Ra <0.5μm, ASME BPE), sensors (conductivity, temperature, pressure, flow, pH, turbidity), and PLC control modules (Rockwell Automation, Siemens Simatic, ABB, B&R, Emerson DeltaV with full audit trail and 21 CFR Part 11 compliant electronic signatures). Major suppliers include Baosteel, Outokumpu (stainless), Emerson (Rosemount sensors), Siemens, Rockwell Automation, ABB; Apex, Alfa Laval (pumps/valves). Downstream customers include pharmaceutical companies such as Pfizer, Roche, Bayer, Novartis, Merck, Sanofi, GSK, AstraZeneca; food and beverage companies such as PepsiCo, Coca-Cola, Nestlé, Danone, Unilever, Kraft Heinz, Mars; and biopharmaceutical CDMOs such as Lonza, Samsung BioLogics, Fujifilm Diosynth Biotechnologies, Catalent, Thermo Fisher Patheon, Boehringer Ingelheim, WuXi Biologics. In the future, these systems will rapidly develop in the direction of intelligence (remote monitoring via IIoT dashboards, predictive maintenance (sensor drift, pump seal wear, valve seat degradation), automated CIP/SIP recipe optimization by product/residue based on inline sensors), energy efficiency (reduced water consumption: 15-30% savings via final rinse recovery, re-use, steam traps, condensate return, heat recovery on waste streams, reduced steam demand with shorter cycle times, higher heat transfer coefficients), and modular customization (Skid-mounted, sanitary clamp connections, multi-product facility flexibility). Moreover, they are poised to gain significant market share amidst increasingly stringent global GMP compliance (annex 1 Manufacture of Sterile Products requires contamination control strategy with defined limits for endotoxins/particulates after cleaning, new EU GMP Annex 1 2025 addendum) and food safety regulations (FSMA Preventive Controls for Human Food, Safe Quality Food (SQF) code edition 9, Global Food Safety Initiative (GFSI) benchmarked standards, BRCGS Food Safety Standard issue 9 requiring validated cleaning effectiveness, allergen changeover, clean-out-of place (COP) supplements equipment deep clean).
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/6097793/mobile-cip-and-sip-devices
1. Executive Summary: Addressing Core User Needs in Hygienic Processing
Biopharmaceutical plant engineers, food safety managers, and pharmaceutical validation specialists face three persistent challenges: achieving validated cleanliness (removal of product residues, endotoxins (bioburden pharmaceutical & biologics), cleaning agent residues, allergen cross-contamination (e.g., gluten, peanut, dairy, soy for food industry changeover, all sanitary design/cleanability) between batches without disassembly, reducing sterilization cycle time (steam SIP of bioreactors, tanks, filling lines — every unnecessary minute reduces production capacity, especially for multiproduct facilities and CMOs with frequent changeovers), and maintaining GMP audit compliance (EU GMP Annex 1 2025 (Contamination Control Strategy (CCS), 21 CFR Part 11 (electronic records), FDA data integrity guidance, ALCOA+ data integrity principles for CIP/SIP cycles: attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, available). The mobile CIP/SIP device—available in manual (push-button local control, simple cycles), semi-automatic (PLC-controlled with recipe-based cleaning, touchscreen HMI but limited data logging for GMP, often skid-mounted, used in pilot plants, R&D labs, smaller co-packing/third party logistics 3PL food manufacturers without full automation infrastructure), and fully automatic (complete integration with facility DCS/Batch system (DeltaV, Rockwell PlantPAx, Siemens Simatic PCS 7, Emerson Syncade, Werum PAS-X MES), recipe management (OIP), full 21 CFR Part 11 compliant audit trail (electronic signatures, user access levels, password aging/2FA), automated report generation, remote access, SCADA integration, for large multinational pharma/ biopharma/food) —provides mobile (casters, modular connections to sanitary process ports via tri-clamp fittings) cleaning and sterilization for vessels (100-20,000L bioreactors, mixing tanks, formulation tanks), filling lines (vial/syringe/cartridge, blow-fill-seal, aseptic isolators, RABS), centrifuges, homogenizers, tablet presses, fluid bed dryers, coating pans, pipe loops, and heat exchangers.
Industry growth drivers in H1 2026 include new biopharma capacity expansion (600+ new biologics manufacturing facilities under construction globally 2025-2027, fed by US BIOSECURE Act, China biotech, Korea, Ireland, Singapore), regulatory enforcement of EU GMP Annex 1 (2025 addendum requiring environmental monitoring, contamination control strategy, documented CIP/SIP validation), and food industry allergen risk management (labeling regulations, FSMA preventive controls, separation of allergen-free vs. containing lines, changeover verification time reduction.
2. Market Size & Recent Policy Drivers (Last 6 Months)
Market Update: Mobile CIP/SIP device market grew 8.1% YoY in H1 2026. Three factors drive growth:
- Biopharma capacity expansion: 120+ new drug substance (DS) and drug product (DP) biologic facilities (2025-2027, EVP, greenfield, brownfield retrofit, modular cleanrooms). Mobile CIP skids flexible for multi-product suite (campaign manufacturing). Single-use bioreactor final fill likewise.
- Regulatory surveillance & FDA inspection EU GMP Annex 1 (2025 addendum EMA/WHO), USP <1058> analytical instrument qualification, contamination control strategy CFU, endotoxins, cleaning validation.
- Food safety & allergen management: FSMA Preventive Controls for Human Food, allergen preventive controls, validation frequency (not just verification).
Technical bottleneck: Mobile docking with stationary vessel (docking alignment, tri-clamp, gasket, steam sealing before SIP cycle, risk of steam leak/burn, automatic docking preferred high cost.
3. Segment Analysis: Manual vs. Semi-Automatic vs. Fully Automatic
Manual (10% of 2025 revenue, declining -1% CAGR – legacy):
- Description: Local manual valve operation (butterfly, ball, diaphragm), simple timers, limited data logging. No HMI or basic push-button ON delay timer. Lowest cost.
- Applications: Small R&D, pilot plant (<100L), contract lab, legacy plant without DCS.
- Advantages: Lowest capital ($25,000-60,000), simple for occasional (< once/week).
- Challenge: No audit trail, not 21 CFR Part 11 electronic signature, operator dependent repeatability variation, higher labor.
Semi-Automatic (35% of 2025 revenue, growing at 6.5% CAGR – mid-tier):
- Description: PLC (Siemens S7-1200, MicroLogix), HMI touchscreen 7-12″. recipe selection, user login/password, basic audit trail storage (USB, SD, network drive). Limited trending, batch report printing. No full DCS integration.
- Applications: Mid-size pharma (300-2,000L), food pilot, CMO multi-product may not integrate with client MES.
- Advantages: Good for GMP (audit trail), standalone skid (no high-level integration cost).
- Challenge: Data must be manually exported/reviewed, not centralized.
Fully Automatic (55% of 2025 revenue, growing at 9.5% CAGR – fastest growing):
- Description: Full DCS/Batch integration (DeltaV, PlantPAx, PCS 7). Full recipe management, 21 CFR Part 11 compliant (electronic signatures, audit trail, eBatch record). Remote access (SCADA, IIoT dashboard), predictive maintenance (vibration, motor current, dead-band). ERP/MES integration (SAP, Werum PAS-X, Syncade).
- Applications: Large pharma (500-20,000L, multi-product, high changeover frequency), biotech (mAbs, gene therapy, cell culture, vaccine).
- Advantages: Paperless validation, reduced labor, fast changeover (<60 min), highest OEE.
- Challenge: High capital ($150,000-400,000+), long integration (6-12 months), high skill validation.
Industry Vertical Insight (Pharma vs. Biotech vs. Food vs. CMO):
Pharma (small molecule, OSD, solid dose) semi or auto. Biotech (mAbs, gene therapy, cell therapy) fully auto (high value batch). Food (dairy, beverage, liquid processing, wet) semi-auto (allergen changeover may pay auto). CMO versatility multi-client, fully auto.
4. Competitive Landscape & Exclusive Observations
Global Leaders (bio/pharma process hygienic equipment specialists):
- Suncombe (UK): 20% share, mobile CIP/SIP skids, strong biopharma. H1 2026: $163 million (+8% YoY).
- INOXPA (Spain), Actini Group (France), Brinox (Denmark): 15%, 10%, 8%. Food, dairy, beverage.
- HTS SA, Propack Technologies, SYSBIOTECH, Pura-Sys Pharma, IUS Equipment, Precikot, Techno Service Egypt, BiOZEEN, Bhagwati Pharma, Neelam Industries: regional, smaller.
Exclusive Observation (June 2026): ”Single-use mobile CIP/SIP” — disposable flow paths, wetted parts replaced after each batch, eliminating stationary hard-piped stainless steel’ cleaning validation. Emerging for small-scale biotech (flexible, multi-product). Cost $3,000-10,000 per batch consumable.
5. Regional Outlook & Forecast Adjustments (2026–2032)
- Asia-Pacific (largest, 45% share): CAGR 8.5% (China biomanufacturing/CDMO, India API generics, Singapore/Ireland/contract).
- North America: CAGR 7.2% (US biopharma BIOSECURE, food safety FSMA).
- Europe: CAGR 7.0% (Germany, Switzerland biopharma, Ireland CDMO, UK)
6. Strategic Recommendations
- For biopharma plant engineers (mAbs, vaccine, cell/gene therapy, multi-product facility): Fully automatic mobile skid (full DCS integration, 21 CFR Part 11, recipe management) for high-value batches, frequent changeover.
- For food safety managers (dairy, beverage, wet, high-allergen changeover): Semi-automatic (audit trail, allergen cleaning verification via inline conductivity, pH, turbidity). Allergen changeover without disassembly.
- For CIP/SIP system manufacturers: Sensorized skid (remote monitoring, predictive maintenance). Eco-mode energy saving (water 30%, steam 15%). Single-use hybrid. Reduced cost semi-auto for SMEs.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
